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OBJECTIVES: To suggest alterations to cost-effectiveness models of biologics for 
moderate to severe psoriasis that would account for the utility of partial 
responders. METHODS: Clinical guidelines dictate that, for the continuation of a 
biologic in treatment of moderate to severe psoriasis, a 75% improvement from 
baseline on the Psoriasis Area Severity Index (PASI) must be achieved which 
serves as a Minimum Clinical Endpoint (MCE). However, patients achieving a 
PASI 50% improvement may also continue treatment if supplemented by a 
minimally important difference (MID) in health-related quality of life (5-point 
improvement on the Dermatology Life Quality Index (DLQI)). Since cost-
effectiveness models of biologic medications for treatment of psoriasis do not 
account for the utility of any patients achieving a PASI 50% improvement, a 
systematic review was conducted to identify whether patients achieving a PASI 
50% improvement also achieved a 5-point DLQI improvement in large RCTs. 
Statistical inference from data obtained therein was used to modify equations 
used in cost-effectiveness calculations. RESULTS: The systematic review 
returned 8 studies that reported DLQI improvements in terms of Mean ± SD, 
stratified by increasing PASI response. Each study returned mean DLQI scores for 
patients with a PASI 50% improvement that were within one standard deviation 
of a 5-point DLQI improvement. This finding drove proposed alterations in which 
patients with a PASI 50% improvement are counted as “partial responders” or 
“non-responders” based on the probability of whether or not a 5-point DLQI 
improvement was attained. CONCLUSIONS: The literature confirms that 
patients with severe psoriasis can achieve a MID in DLQI improvement without 
achieving an MCE in PASI improvement. This study proposes alterations to the 
methodology of cost-effectiveness calculations that recognize the meaningful 
improvement in outcomes achieved by this subset of patients. Nevertheless, 
future studies should examine how these alterations affect overall cost-
effectiveness of biologics for psoriasis.  
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OBJECTIVES: To apply national demographic and epidemiologic data in China to 
a mathematical model designed to estimate the public health impact of PCV7 at 
a population level. METHODS: Demographic data were collected from 2008 
census .The incidence rate of all-cause hospitalized pneumonia and 
pneumococcal meningitis was searched from international literature. Data were 
applied to a 10-year Markov model to estimate the impact of vaccination on 
those diseases. Projections of the diseases over a 10-year period are estimated 
under assumptions of no vaccination and full vaccination of the national birth 
cohort. Details of the model calculations as applied to the United States were 
published elsewhere. RESULTS: According to model estimation, over 730,000 
cases of pneumococcal meningitis and over 100 million cases of pneumonia that 
would occur in unvaccinated children and adults in China over a 10-year period, 
as well as causing over 5.3 million deaths. More than 30 million cases and 
420,000 deaths would occur in children under 5 years of age. The inclusion of 
universal vaccination of infants with PCV7 was expected to reduce the overall 
burden by 5.5 million cases, largely due to the reduction in all-cause pneumonia, 
with nearly 2 million cases of pneumonia estimated to be reduced in children 
under 5 years old. CONCLUSIONS: Widespread use of PCV7 in China is expected 
to have a significant impact on hospitalizations and death due to all-cause 
pneumonia and meningitis in vaccinated children.The potential impact of 
widespread use of PCV7 on unvaccinated persons due to herd protection adds to 
the overall public health impact significantly.  
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OBJECTIVES: The traditional audience for US health economic (HE) models has 
been payers, but the changing health care reimbursement environment suggests 
a stronger role for provider-perspective models. The US health care system is 
moving toward quality incentive payment schemes and increased risk sharing 
for providers. This shift in payment will impact provider incentives and priorities 
as they relate to technology adoption. Here, we look at how the transition from 
fee-for-service payments to bundled payments in accountable care organizations 
(ACO) will impact health economic modeling for manufacturers of medical 
devices. METHODS: Expert analysis was conducted on a comprehensive review 
of publicly available literature, in-depth discussions with hospital and ACO 
administrators, and drawing on lessons learned from developing models for 
device manufacturers. Relevant model inputs, time horizon, outcomes and 
structure were examined to provide recommendations for improving the 
usefulness of HE models for hospital and ACO decision-makers. RESULTS: Of the 
6 administrators interviewed, 5 (83.3%) felt that technology adoption decisions 
will move beyond the individual physician and extend to the system-wide level. 
When asked to consider what outputs would be most useful for benefit design 
and coverage decision-making, administrators cited the total cost of procedure 
(include hospital length-of-stay and hospital resource utilization), post-operative 
care and cost associated with complications from the procedure, in rank order. 
ACO administrators reported that time horizons considered as part of budget 
impact modeling should be extended from the traditional benefit year to up to 3 
years, depending on the length of the episode of care. CONCLUSIONS: Medical 
device manufacturers need to create data and tools  
that demonstrate efficiency gains and cost-effectiveness from a hospital and 
ACO purchasing strategy. The ability to demonstrate both a clinical and 
economic value to hospitals and ACOs, who are increasingly the key decision-
makers for technology adoption, will be important to achieving successful 
market access.  
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OBJECTIVES: Where data is sparse, expert opinion may be used to populate 
decision analytic models. Elicitation techniques which capture uncertainty 
associated with expert opinion (i.e. elicit probability distributions) have analytic 
benefits over obtaining single values from experts but may be difficult to carry 
out and the methodological implications of different techniques are poorly 
understood. To assess current use of elicitation techniques which incorporate 
experts’ uncertainty, we conducted a methodological review of the use of 
elicitation in economic models. METHODS: The review was systematic in 
approach. Electronic databases (MEDLINE, EMBASE and CRD) were searched 
using an explicit strategy. Studies describing their approach to elicitation were 
included. Data was abstracted on pre-defined aspects of the elicitation 
technique. The synthesis was narrative. RESULTS: Twelve articles were included. 
The median number of experts per study was five (range 3-23). In eleven studies 
(91.7%), experts were asked individually. Only one study reported a group 
elicitation exercise. The most frequently used approaches to elicitation were the 
histogram technique and the bisection method. Elicitation was used to inform 
effectiveness (for treatments), performance (for diagnostic tests) or disease 
progression parameters, with only one study eliciting resource use. The elicited 
parameters were in the form of a proportion in seven studies, time to event in 
four studies, rate in three and relative risk in two studies. Across these studies, 
there was heterogeneity in both approach and reporting of what we considered 
to be key aspects of the elicitation process. CONCLUSIONS: Judged by the studies 
identified in the review, elicitation can be useful and is valued. Efforts should be 
made to improve reporting of elicitation in health technology assessments, with 
the aim of not only of improving the description of individual studies, but also to 
contribute towards establishing accepted good practice in elicitation in the 
context of decision analytic modeling.  
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OBJECTIVES: To figure out what disease models equations/hypothesis work best 
on what populations. METHODS: 1) Extraction of multiple published disease 
models/risk equations for cardiovascular disease and multiple diabetic 
population distributions and outcomes. The populations used were UKPDS, 
ASPEN, ADVANCE, ACCORD, NDR, KP. 2) Implementation of these components 
and systematic cross validation of models against populations using micro-
simulation and relying on computing power. 3) Defining a fitness score to 
convert of multiple outcome differences into a single number. 4) Defining 
different queries with weights to rank model / population fitness. The methods 
avoid using individual data and rely on more accessible summary data. 
RESULTS: The fitness score matrix uses color coding and ranking to visually 
demonstrate the fitness between 6/34 populations/cohorts and 64 combinations 
of published risk equations and hypotheses. The results show that different 
combinations of risk equations behave differently on different population 
cohorts. For each query, the system ranks the models. Models that implement 
the following two corrections generally behaved better: 1) Temporal correction 
for treatment improvement; 2) Biomarker change introduced in the first year. 
CONCLUSIONS: 1) Modelers should talk in terms of best fitting model rather than 
best model since in many cases, the best model changes according to specifics of 
the query. 2) Disease modelers who develop risk equations should add a 
temporal correction term within their risk equations to prevent model outdating. 
3) The fitness score function allows comparing behavior of different populations 
using a similar metric and provides a visual explanation of current 
understanding of disease progression.  
 
PRM89  
PATIENT-LEVEL SIMULATION MODELING FOR ECONOMIC EVALUATIONS: 
OPPORTUNITIES AND CHALLENGES IN A PRACTICAL SETTING  
Herring W, Mladsi DM, Mauskopf JA 
RTI Health Solutions, Research Triangle Park, NC, USA  
OBJECTIVES: In the spectrum of methodologies used to conduct economic 
evaluations, patient-level simulation modeling is noteworthy for its flexibility in 
reproducing patient experiences that closely mirror reality. This flexibility is 
especially important when modeling diseases with continuous or multi-
dimensional health states or with non-Markovian dependence on disease 
history, but often comes at the expense of advanced data and software 
requirements and reduced computational efficiency. Methods for exploiting the 
opportunities while mitigating the challenges associated with using simulation 
modeling are needed. METHODS: Based on our experience developing patient-
level simulation models in Microsoft Excel for a complex, progressive disease, we 
identified steps that can be taken during the development and presentation of a 
simulation model to capitalize on the advantages inherent in the flexibility and 
transparency of this approach while mitigating some of the the associated 
